Meranzin

Synonyms: 橙皮内酯
Meranzin 是一种口服有效的抗抑郁剂和 GHSR 调节剂,通过饥饿素-生长激素促分泌素受体通路显著提高海马体中脑源性神经营养因子和 p-mTOR 的表达水平,并调控海马-丘脑-基底神经节回路的血氧水平依赖信号,减弱奖赏系统激活、促使相关激素水平恢复正常,从而有效改善抑郁样行为和胃肠动力不足,可用于抑郁症及重度抑郁症的相关研究。
产品编号: MS-D51497 纯度: 98.0% CAS No.: 23971-42-8 分子式: C15H16O4 分子量: 260.29
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Meranzin 是一种口服有效的抗抑郁剂和 GHSR 调节剂,通过饥饿素-生长激素促分泌素受体通路显著提高海马体中脑源性神经营养因子和 p-mTOR 的表达水平,并调控海马-丘脑-基底神经节回路的血氧水平依赖信号,减弱奖赏系统激活、促使相关激素水平恢复正常,从而有效改善抑郁样行为和胃肠动力不足,可用于抑郁症及重度抑郁症的相关研究。

生物实验数据

生物活性 Meranzin is an orally active antidepressant and GHSR modulator that significantly increases the expression levels of brain-derived neurotrophic factor and p-mTOR in the hippocampus via the ghrelin-growth hormone secretagogue receptor pathway, and regulates blood oxygen level-dependent signals in the hippocampus-thalamus-basal ganglia circuit to attenuate reward system activation and restore related hormone levels to normal, thereby effectively ameliorating depression-like behaviors and gastrointestinal hypomotility, and can be used for research on depression and major depressive disorder.
体内研究
(In Vivo)

Meranzin (9-18 mg/kg;单次给药) 可通过生长激素释放肽相关的海马 BDNF/p-mTOR 信号通路及 HTB 环路活性调控,改善急性强迫游泳诱导大鼠的抑郁样行为及运动迟缓状态。
Meranzin (18 mg/kg;单次给药) 可通过 FST 和 TST 检测结果降低野生型小鼠的抑郁样行为。
Meranzin (18 mg/kg;单剂量) 在通过 FST 和 TST 结果评估时,无法减轻 GHSR 敲除小鼠的抑郁样行为。
Meranzin (10 mg/kg;灌胃;每日;连续 7 天) 在慢性不可预测温和应激 (UCMS) 诱导的抑郁大鼠中产生显著的抗抑郁样和抗焦虑样作用,可使下丘脑-垂体-肾上腺 (HPA) 轴功能恢复正常,增加海马脑源性神经营养因子 (BDNF) 的表达,并修复 UCMS 诱导的奖赏系统和边缘系统异常血氧水平依赖 (BOLD) 激活。

Animal Model: Sprague-Dawley (8 rats per group; acute forced swimming-induced model)
Dosage: 9 mg/kg; 18 mg/kg
Administration: single dose
Result: Improved depression-like behavior (FST, OFT) and hypomotility (GE, IT) (all P<0.05).
Significantly stimulated BDNF and p-mTOR protein expressions in the hippocampus (both P<0.01).
Modulated activity in the hippocampus-thalamus-basal ganglia (HTB) circuits as measured by BOLD foci.
Had its effect on FST and GE inhibited by ghrelin antagonist [D-Lys3]-GHRP-6 (P<0.05).
Had its stimulation of hippocampal BDNF and p-mTOR expressions prevented by [D-Lys3]-GHRP-6 (P<0.01).
Had its modulation of HTB circuit activity inhibited by [D-Lys3]-GHRP-6.
Animal Model: Wild-type (8 mice per group)
Dosage: 18 mg/kg
Administration: single dose
Result: Alleviated depression-like behavior (FST, TST) in wild-type mice.
Animal Model: Growth hormone secretagogue receptor knockout (GHSR KO)
Dosage: 18 mg/kg
Administration: single dose
Result: Showed no antidepressant effects in GHSR KO mice, with no observed changes in FST or TST outcomes.
Animal Model: Wistar (adult male, 180−220 g, UCMS-induced depression model)
Dosage: 10 mg/kg
Administration: i.g.; daily; 7 days
Result: Significantly reduced immobility time in the forced swimming test (P < 0.001 vs UCMS group).
Significantly increased sucrose preference index (P < 0.01 vs UCMS group).
Significantly increased total distance travelled in the open-field test (P < 0.01 vs UCMS group).
Significantly reduced plasma adrenocorticotropic hormone (ACTH) (P < 0.05 vs UCMS group), corticosterone (CORT) (P < 0.01 vs UCMS group), and acylated ghrelin (AG) (P < 0.01 vs UCMS group) levels, normalizing them to near control levels.
Significantly increased brain-derived neurotrophic factor (BDNF) expression in the hippocampal dentate gyrus (P < 0.01 vs UCMS group).
Attenuated UCMS-induced increased BOLD activation in reward system and limbic system brain regions, including the striatum, septal area, thalamus lateral nucleus group, bed nucleus of stria terminalis, hippocampus, midbrain superior colliculus, nucleus accumbens, and third ventricle.
Increased BOLD activation in the right auditory cortex, right amygdaloid body, left sensory cortex, right third ventricle, and left temporal association cortex.
Reversed UCMS-induced changes in BOLD signals in the right amygdaloid body and right visual cortex, and decreased BOLD signals in bilateral hypothalamus preoptic regions.
性状 固体
颜色 White to off-white

化学信息

分子量 260.29
分子式 C15H16O4
CAS No. 23971-42-8
别名 橙皮内酯

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (7.68 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, sealed storage, away from moisture and light

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (384.19 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.8419 mL19.2093 mL38.4187 mL96.0467 mL
5 mM0.7684 mL3.8419 mL7.6837 mL19.2093 mL
10 mM0.3842 mL1.9209 mL3.8419 mL9.6047 mL
15 mM0.2561 mL1.2806 mL2.5612 mL6.4031 mL
20 mM0.1921 mL0.9605 mL1.9209 mL4.8023 mL
25 mM0.1537 mL0.7684 mL1.5367 mL3.8419 mL
30 mM0.1281 mL0.6403 mL1.2806 mL3.2016 mL
40 mM0.0960 mL0.4802 mL0.9605 mL2.4012 mL
50 mM0.0768 mL0.3842 mL0.7684 mL1.9209 mL
60 mM0.0640 mL0.3202 mL0.6403 mL1.6008 mL
80 mM0.0480 mL0.2401 mL0.4802 mL1.2006 mL
100 mM0.0384 mL0.1921 mL0.3842 mL0.9605 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础